Literature DB >> 3396262

Interindividual and intraindividual variability in acetylation: characterization with caffeine.

B G Hardy1, C Lemieux, S E Walker, W R Bartle.   

Abstract

The degree of interindividual and intraindividual variability in acetylator activity was investigated with caffeine used as a probe of enzyme activity. Acetylator phenotype and relative N-acetyltransferase activity were estimated in 46 subjects by measuring the urinary ratio of two metabolites, AFMU/1-MX, after a single 300 mg oral dose of caffeine on five separate occasions. Thirty homozygous slow (rr) and 15 heterozygous rapid (Rr) acetylators were identified. The degree of interindividual variability in acetylator activity was observed to be a mean of 32% (range 27% to 36%) and 20% (range 11% to 29%) in the rr and Rr groups, respectively. The mean intraindividual variation on repetitive measurement was 19% (range 6% to 49%) in the rr and 14% (range 7% to 24%) in the Rr acetylator group. Four subjects had apparent changes in acetylator activity with time such that they were unable to be assigned to any one acetylator group. Two of these four subjects exhibited apparent homozygous rapid acetylator activity intermittently during the 5-week trial. This variability may explain, in part, some of the high degree of patient variability observed in the toxicity, efficacy, and drug-related disease associated with acetylated drugs and environmental toxins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396262     DOI: 10.1038/clpt.1988.130

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.

Authors:  A N Leaf; D Neuberg; E L Schwartz; S Wadler; P S Ritch; J P Dutcher; G L Adams
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Effects of moderate exercise on the pharmacokinetics of caffeine.

Authors:  K Collomp; F Anselme; M Audran; J P Gay; J L Chanal; C Prefaut
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

Authors:  D M Grant; K Mörike; M Eichelbaum; U A Meyer
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

4.  Potential artifacts in the use of caffeine to determine acetylation phenotype.

Authors:  B Lorenzo; M M Reidenberg
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

5.  Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Authors:  Alexander Jetter; Martina Kinzig; Michael Rodamer; Dorota Tomalik-Scharte; Fritz Sörgel; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2008-12-13       Impact factor: 2.953

6.  N-acetylation phenotyping using dapsone in a Jordanian population.

Authors:  Y M Irshaid; H F al-Hadidi; M A Abuirjeie; N M Rawashdeh
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.